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305Osteoarthritis and Cartilage Vol. 14, No. 4Introduction
A Task Force of the Osteoarthritis Research Society Inter-
national (OARSI) has previously published a set of guide-
lines for the conduct of clinical trials in osteoarthritis (OA)
of the hip and knee1. Limited material available on clinical
trials of OA of the hand2e4 has prompted OARSI to estab-
lish a separate Task Force to elaborate guidelines encom-
passing special issues relating to hand OA. The Task
Force was composed of academic physicians, clinical phy-
sicians and researchers in the pharmaceutical industry.
Task Force expenses were supported by unrestricted
grants provided by pharmaceutical company representa-
tives (see the Acknowledgments section).
The Task Force elected to produce a set of guidelines that
are based on the published medical literature supplemented
by expert opinion. Small working groups dealt with speciﬁc
aspects of trial design. The Task Force met in whole, or in
part, on four occasions over a 4-year period between 2001
and 2005. Additional modiﬁcations of the guidelines were
made through e-mail correspondence. The Board of Direc-
tors of the OARSI requested further reﬁnement of the guide-
lines document and established a set of workshops at the
OARSI World Congress on Osteoarthritis held in Chicago,
in December 2004. Subsequent e-mail correspondence
was required to address outstanding issues, and the ﬁnal
guidelines were submitted to Osteoarthritis and Cartilage
for independent external review, and to the OARSI Board
of Directors for approval, prior to publication.
As research methods for clinical trials in OA of the hand
have not been as well developed as those for knee and
hip OA2e4, it is anticipated that the methodology for per-
forming clinical trials of drugs for hand OA will evolve as
more is learned. It should therefore be understood that
the following recommendations will need to be modiﬁed
as new information becomes available. Investigators, and
representatives of regulatory and sponsoring agencies,
need to be aware of the need for such changes; and new
methodologies will need to be incorporated into the protocol
design. The Task Force is of the opinion that changes in
protocol design should be based on published data. The
Task Force recommends that developers of new protocols
should utilize credible and validated measures where avail-
able, for primary outcome assessments and should con-
sider including, instruments and measurement techniques
requiring initial or additional validation as additional second-
ary outcome measures.
The guidelines are recommendations, not rigid rules, for
the conduct of clinical trials in OA of the hand. Many of
the recommendations are supported by published clinical
research. However, some recommendations have yet to
be validated and are suggestions based on the best judg-
ment and expert opinion of the Task Force at the time the
guidelines were ﬁnalized. These guidelines have been con-
structed to build upon, and follow the pattern of, previously
published guidelines1.
Objectives for treatment of hand OA
Effective medications for OA may alter symptoms and/or
modify structure and pathology (disease-modifying drugs
for OA). Demonstration of these beneﬁts will depend upon
the trial design, outcome variables and measurement
parameters selected. Trial design needs to take into
account the mechanism and kinetics of action of the thera-
peutic intervention under consideration and the repertoire of
responses expected.The term symptom-modifying drug or agent will be appro-
priate for therapies directed at modifying symptoms. Pain or
function will usually be the primary outcome variable. Fac-
tors that need to be considered in trial design include, but
are not limited to, the pharmacodynamics of the drug, the
time to clinical response, the duration of beneﬁt after
discontinuation of treatment, the route of administration,
the effects on pain/function, the effects on inﬂammation,
the effects on other symptoms and signs of the disease,
and on the frequency and severity of adverse events.
A structure (disease)-modifying drug or agent may have
effects on joint structure/function independent of any direct
effect on symptoms. Studies of therapeutic interventions
that are expected to modify the pathologic process of OA
should measure outcome parameters that reﬂect an alter-
ation in joint structure. Such treatments may prevent the
development of OA, or change the course of OA, once it
has developed. The latter category includes therapeutic
agents that may have potential to stop progression, retard
progression, or reverse existing OA changes. Symptomatic
improvement may occur only after a prolonged period of
administration. The Task Force has not developed a position
on whether symptom response is needed to establish efﬁ-
cacy for a structure-modifying drug. It is clear, however,
that a structure-modifying effect must result in perceptible
clinical beneﬁt within a relevant time point in the patient’s
lifespan. Whether related to symptoms, function or some
other variable, the primary outcome measure should be
clinically relevant to patients with hand OA.
Levels of clinical trials for hand OA
There are no special characteristics of trials for OA of the
hand that require any alteration in the established sequence
of phase 1, 2, 3 and postmarketing phase 4 trials1.
Entering patients into hand OA trials
This section addresses the aspects of study design, in-
cluding the protocol, admission criteria, and selection of the
study population and the deﬁnition of what is to be studied.
For all nonhand OA-speciﬁc issues, the Task Force
recommends following general guidelines for the conduct
of clinical trials5 and previously published OA-speciﬁc
recommendations1.
Baseline assessment should provide information on the
joint sites to be studied, the aetiology (primary, secondary),
the severity of symptoms, structural abnormalities in the
joint, and concomitant therapy and comorbidity2,3.
DEMOGRAPHICS
As a minimum, sociodemographic and clinical data col-
lected at the time of enrollment into the study should include
age (date of birth), gender, menopausal status in women6,7,
height, weight, and years of formal education. The patient’s
primary occupation should be noted and the identiﬁcation of
current or past activities involving intensive use of the
hands (e.g., sports, gardening, playing speciﬁc musical
instruments) is optional but desirable.
DIAGNOSIS
Criteria for the diagnosis of OA should be clearly stated.
Patients should fulﬁll validated criteria for the classiﬁcation
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Rheumatology (ACR)8 (Table I). OA should be classiﬁed as
primary or secondary. Study populations should be as ho-
mogenous as possible, with regard to the presence of pri-
mary or secondary OA. If patients with secondary OA, or
exacerbating factors related to primary OA are included,
the underlying condition should be speciﬁed, and should
be the same in all patients (e.g., post-traumatic arthritis, cal-
cium pyrophosphate deposition disease, hemochromato-
sis). It is suggested, that in studies of patients with
idiopathic OA, patients with secondary OA of the study
joint(s) should be excluded.
Much effort has been devoted to develop deﬁnitions of
hand OA for use in epidemiologic and clinical studies9e15.
Epidemiologic studies require explicit deﬁnitions of hand
OA in order to separate cases from noncases16. These def-
initions may include individuals with and without clinical fea-
tures of hand OA. Therapeutic studies, however, currently
focus on patients with symptomatic hand OA. These may
require case deﬁnitions that differ from those used in epide-
miologic studies. There is no gold standard for case deﬁni-
tion of hand OA at present, and this is an area requiring
further research.
As with OA in other joint regions, it is difﬁcult to divide
hand OA into subsets. Trapeziometacarpal joint (ﬁrst
carpo-metacarpal or ﬁrst CMC joint) OA may exist alone
(estimated as approximately 20% of cases)17, but most
often occurs together with interphalangeal (IP) changes of
OA18. Although protocols may study this group as a subset,
evidence that ﬁrst CMC OA represents a separate entity,
rather than being part of the spectrum of hand OA remains
controversial19e21. The exception could be the subset of the
population with constitutional hypermobility22. However, the
association between hand OA and hypermobility has
recently been called into question23.
It has been suggested that erosive IP OA may be a rela-
tively uncommon, but separate, entity from nodal IP OA,
which could be studied as a subgroup24,25, should sufﬁcient
numbers be available. At present, however, there is no val-
idated, uniformly agreed, and clear-cut deﬁnition of erosive
IP OA for clinical trials; and this is an issue that could be
explored through further research. Based on current evi-
dence, the consensus is that erosive OA is a clinical subset
of generalized OA26 which falls within the deﬁnition of, and
which is part of, the spectrum of hand OA as described in
this document.
Table I
Algorithm for classification of OA of the hand, subcommittee on OA,
American College Of Rheumatology Diagnostic And Therapeutic
Criteria Committee
Clinical
1. Hand pain, aching, or stiffness for most days of prior month.
2. Hard tissue enlargement of >2 of 10 selected hand joints.*
3. Fewer than 3 swollen MCP joints.
4. Hard tissue enlargement of 2 or more DIP joints.
5. Deformity of 2 or more of 10 selected hand joints.*
OA present if items 1, 2, 3, 4 or items 1, 2, 3, 5 are present.
Sensitivity is 92% and speciﬁcity is 98%. Abbreviations:
DIP¼ distal interphalangeal, PIP¼ proximal interphalangeal,
MCP¼metacarpo-phalangeal, CMC¼ carpo-metacarpal. Refer
to: Altman et al.8.
*Ten selected hand joints include bilateral 2nd and 3rd DIP
joints, 2nd and 3rd PIP joints and ﬁrst CMC joints.STUDY JOINT AND DISEASE DURATION
Since hand OA is a polyarticular disease, protocols
should specify the primary joint or region to be studied;
i.e., both hands, the more symptomatic hand (usually the
dominant hand), a single joint, a single ray, or a single
row of joints. This is in contrast to the study of OA in other
joints, where it is recommended that a single joint be pre-
speciﬁed as a target joint for evaluation.
Progression is joint speciﬁc9,27. Joint symptoms and
signs in affected joints evolve independently; and changes
in signs, symptoms, and imaging at one hand OA joint do
not predict the course of OA in another joint. A patient se-
lected for a clinical trial on the basis of a painful hand joint,
may experience remission of symptoms in that joint within
a few weeks or months. This may, or may not, coincide
with development of symptoms in a previously asymptom-
atic ﬁnger joint. In general, symptoms of hand OA are tran-
sient, unpredictable, and irregular. The most severely
affected joints on plain radiographs are not necessarily
symptomatic, and are not consistently the most symptoma-
tic28e30. As a consequence, advanced radiological changes
are often associated with an absence of pain or functional
impairment. However, there is some evidence that radio-
graphic severity does correlate with the degree of deformity
and bony enlargement31,32. The design of the protocol may
focus on a set of hand joints or the most symptomatic joint,
on both hands, or on the more symptomatic hand. In all
cases, information on the status, and evolution during the
study, of the other hand joints that are not being speciﬁcally
investigated should be appropriately recorded.
Because of symptom variability, agents directed at symp-
tom-modiﬁcation may need to be administered for 4e6
weeks. Even though symptom response can often be deter-
mined in 2 weeks, it is appropriate to test durability and
safety in longer trials. The Task Force recommends a study
duration sufﬁcient to permit the detection of a clinically-
important statistically-signiﬁcant, between-group, difference
which may vary according to the type of intervention/drug
tested. Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
likely to be effective more rapidly than symptomatic slow-
acting drugs in OA (SYSADOA). The minimum duration of
study should be of the order of 4e6 weeks, although studies
to evaluate the durability of the response should be longer
in duration, possibly of the order of 6 months. For new drugs
where insufﬁcient safety data are available, long-term
safety should be assessed in phase 3 trials of sufﬁcient
duration, possibly up to 12 months for systemic treatments.
In trials directed at symptom-modiﬁcation, follow-up after
treatment has been stopped, and can be used to study
the persistence of the therapeutic effect. The Task Force
recommends a minimal duration of 1 year, and preferably
2e3 years, to optimize identiﬁcation of structural changes.
Validated imaging methodology will be needed, and can
be explored through further research.
RADIOGRAPHS
Classically, the diagnosis of OA in epidemiologic studies
has relied on the characteristic radiographic changes de-
scribed by Kellgren and Lawrence in 195733 and illustrated
in their Atlas of Standard Radiographs (Table II)34.
The radiographic entry criteria should be appropriate for
the speciﬁc study objective. For example, a cohort which in-
cludes patients with advanced radiographic changes might
be appropriate in studies of a symptom-modifying drug,
while a cohort limited to those with minimal radiographic
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ture-modifying drug intended to retard progression.
Potential limitations of the use of the KellgreneLawrence
grading scheme have been noted16,35,36. These include
overemphasis on the osteophyte as a marker of disease,
and severity of disease, and difﬁculties in interpretation,
leading to poor interobserver and intersite agreement. In
an attempt to address some of these limitations of a global
grading scale, several groups have developed radiographic
grading schema which focuses on individual radiographic
features of OA at speciﬁc joint groups; and reliable grading
scales have now been published for the hand27,37e39. Using
a published atlas, trained readers have been shown to have
excellent intrareader and very good-to-excellent inter-
reader reproducibility in measuring the presence and sever-
ity of OA of the hand28,37e40. Kessler et al.29 have proposed
a rapid hand scale based on a published atlas38. The
method of Verbruggen and Veys27,41 may permit a more de-
tailed evaluation of disease progression.
The radiographic severity of OA in each patient should be
semiquantiﬁed and documented using either aggregate ra-
diographic criteria (e.g., Kellgren and Lawrence scale)33,42
or grading of speciﬁc radiographic feaptures27,38,39. A cur-
rent radiograph should be obtained upon entry to a struc-
ture-modifying trial. It is recommended that baseline
radiographs for characterization of patients in trials of
symptom-modifying drugs should be obtained within 3
months, and the interval between obtaining the radiograph
and the start of the trial should not be longer than 12
months. The range of grades to be used for entry criteria
should be prespeciﬁed in the protocol, in the expectation
that with successful randomization, variations in grade
among treatment and placebo (or control) groups should
be comparable.
Table II
Grades of severity of OA in the small joints of the hands, Atlas of
Standard Radiographs
Distal IP joints
Grade 1: Normal joint except for one minimal osteophyte.
Grade 2: Deﬁnite osteophytes at two points with minimal sub-
chondral sclerosis and doubtful subchondral cysts, but good joint
space and no deformity.
Grade 3: Moderate osteophytes, some deformity of bone ends
and narrowing of joint space.
Grade 4: Large osteophytes and deformity of bone ends with
loss of joint space, sclerosis and cysts.
Proximal IP joints
Grade 1: Minimal osteophytosis at one point and possible cyst.
Grade 2: Deﬁnite osteophytes at two points and possible nar-
rowing of joint space at one point.
Grade 3: Moderate osteophytes at many points, deformity of
bone ends.
Grade 4: Large osteophytes, marked narrowing of joint space,
subchondral sclerosis and slight deformity.
First CMC joint
Grade 1: Minimal osteophytosis and possible cyst formation.
Grade 2: Deﬁnite osteophytes and possible cysts.
Grade 3: Moderate osteophytes, narrowing of joint space and
subchondral sclerosis and deformity of bone ends.
Grade 4: Large osteophytes, severe sclerosis and narrowing of
joint space.
Refer to: Kellgren et al.33 Lane et al.104. [Reproduced from Sil-
man, Hochberg (1993). Epidemiology of the Rheumatic Diseases.
Oxford University Press, Oxford].STUDY POPULATION
The patient population (e.g., community-based primary
care, clinic-based secondary care or hospital-based tertiary
care) should be deﬁned in the protocol.
Examples of subjects who might be considered for inclu-
sion or exclusion might be young (<45 years old), low-risk
populations, or a variety of high-risk populations, as well
as speciﬁc populations, such as those with isolated ﬁrst
CMC involvement.
For studies of symptomatic response, the level of symp-
toms at baseline should be of sufﬁcient severity to permit
detection of change (see Deﬁnition of severity below). Def-
inite radiographic changes of OA are required and these
should be graded using a validated scale and/or atlas.
For studies of structure-modifying therapeutic agents,
special subpopulations of subjects, who are at high risk for
development of OA, or rapidly progressive OA, may be ad-
vantageous. Selection criteria for structure-modifying trials
should include at least two radiographically affected joints
with aKellgren and Lawrence radiographic grade233. Alter-
natively, investigators may utilize two joints at the J, S, E or R
phase of the Verbruggen anatomical scoring system27.
DEFINITION OF SEVERITY
In trials of symptom-modifying drugs minimum levels of
symptom severity and symptom duration should be speci-
ﬁed. Patients should have pain and tenderness in at least
two IP or one CMC joint, or in a combination of IP and
CMC joints. Pain should have been present for at least
half of the days in the previous month and for at least 48 h
prior to the screening visit. There should be pain in a joint
that has been shown to have OA on a plain radiograph.
Care should be taken to exclude subjects with referred
pain (e.g., palmar tenosynovitis, carpal tunnel syndrome)2,3.
There is no current consensus on what minimum level to
set for pain severity on entry. It is proposed that on entry to
a study there will be a hand pain score of at least
30e40 mm on a 100 mm-Visual Analog Scale (VAS) or at
least 1 or 2 on a 5-point Likert (LK) Scale (0¼ no pain;
4¼ extreme pain) after withdrawal of analgesic/anti-
inﬂammatory medications (see Administration of study med-
ication/treatment).
There is also no current consensus on what minimum
level to set for the severity of dysfunction on entry. It is pro-
posed that for entry, into studies where function is a primary
or co-primary outcome, patients should rate their disability
as at least 25% of the scale length, e.g. 5 (out of a maxi-
mum of 30) points using the Functional Index for Hand
Osteoarthritis (FIHOA)44e47, which was the cut-off value
shown to discriminate between symptomatic and nonsymp-
tomatic hand OA patients44, 9 (out of a maximum of 40)
using the AUSCAN LK function subscale, or 225 F (out
of maximum of 800) on the AUSCAN VA function sub-
scale48e54, as suggested by the authors.
In trials of structure-modifying drugs the study population
should have a Kellgren and Lawrence radiographic grade of
2 or 3 (or equivalent) in the hand joint(s) to be studied33, or
alternatively, a radiographic S or J phase using the Verbrug-
gen Scoring system (Table III)27,41. It is proposed that OA of
at least two IP joints or one CMC joint be present on the
screening examination2,3.
There is no published data that allow one to make evi-
dence-based recommendations, regarding the degree or
extent of joint involvement required for disease prevention
trials, in order to allow detection of new lesion development,
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Summary of radiological outcomes and scales for structure-modification trials
Outcome Recommended Could be recommended
may require further
validation or precision
on instrument
Could be interesting
but requires validation
Radiographic case deﬁnition KellgreneLawrence grading;
Verbruggen anatomical
scoring system
Use of a validated atlas Magnetic Resonance
Imaging
Identiﬁcation of patients
at risk of progression
Radionuclide bone scan Computerized digital
infrared thermal imaging
Radiographic assessment
of OA progression
KellgreneLawrence grading;
Kallman grading scale;
Verbruggen anatomical
scoring system and grading
of progression; For all
grading systems, each
feature for each joint should
be scored and analyzed
Global scoring:
OA yes/no
Use of a published Atlas;
Magnetic Resonance
Imagingin an acceptable period of time. In these circumstances the
Task Force recommends that a low number (e.g., no more
than one third of IP joints (i.e., six of 18)) should be involved
at baseline, until this issue is clariﬁed by further research.
Because of the high frequency of involvement, the IP joints
are appropriate sites for study in prevention trials. Each
protocol should set a limit on the number of Kellgrene
Lawrence grade 4 changes permitted at entry2,3. Alterna-
tively, the limit could be based on the number of E or R
phases in the Verbruggen Scoring system27,41.
INCLUSIONS/EXCLUSIONS
Inclusion criteria should be clearly deﬁned and should
specify the population to be studied by age, gender, diag-
nostic criteria, joint with OA, types of and level of symptoms,
and radiographic grade.
Exclusion criteria should also be clearly deﬁned with re-
gard to secondary OA, level of symptoms, radiographic
grade, and comorbid diseases, as well as previous condi-
tions of concern such as peptic ulcer disease, if a drug is
perceived to have ulcerogenic potential. Exclusion of con-
comitant medications, pregnancy/contraception and recent
treatment with intra-articular (IA) corticosteroids is also rec-
ommended. A minimum period of 1 month should elapse
between the time of the IA injection of a depocorticosteroid
and enrollment in a trial55,56. There should be a 6-month in-
terval between the time of IA injection of a hyaluronate and
enrollment in a trial. The necessity for, and appropriate
duration of, a washout period (e.g., 3e6 months) for
slow-acting symptom-modifying drugs should always be
considered, and especially when the study drug itself is
a slow-acting drug for symptom relief.
Additional exclusions recommended include signiﬁcant
injury to the affected joint within 6 months of trial enrollment;
use of assistive devices such as a cane or crutch, con-
comitant rheumatic disease (e.g., inﬂammatory rheumatic
disease, cutaneous psoriasis, polyarticular chondrocalcino-
sis, gout, carpal tunnel syndrome, palmar tenosynovitis,
trigger ﬁnger, and ﬁbromyalgia), or poor general health in-
terfering with compliance or assessment2,3.
OA HISTORY
The OA history is used to characterize the study popula-
tion and should include the location and number of symp-
tomatic OA joints, the presence of knee or hip OA, theduration of symptoms, the history of previous medications
for OA, the use of splints, and any history of IA injections
of depocorticosteroids or hyaluronan including the date of
the most recent injection; and any history of previous
hand surgery or other surgical procedures.
OTHER MEDICAL HISTORY
Other items of history at baseline that may be of value in-
clude a history of smoking, the patient’s hormonal status in
peri and postmenopausal women and any history of con-
comitant chronic disease, or medication, e.g., estrogens,
anti-inﬂammatory drugs.
PHYSICAL EXAMINATION OF THE TARGET JOINTS
Baseline information about the target joint or joints helps
to characterize the study population, and provides refer-
ence data for assessing how variables of interest have
changed during the course of treatment. Evidence of inﬂam-
mation and joint deformity should be noted. A complete
standardized physical examination of hand joints should
be performed at baseline, including: the description and
number of symptomatic joints (e.g., painful joints), the
description and number of tender joints, the description
and number of Heberden/Bouchard nodes, the description
and number of joints painful on pressure (on a diagram), and
joints affected by lateral deviation, subluxation of the
ﬁrst thumb metacarpal, and if appropriate the number of
inﬂamed joints as deﬁned by redness, a recent exacerba-
tion of pain, and soft peri/articular tissue swelling. This
examination should be performed again at the end of
the trial and may be considered for use as one of the
secondary outcome measurements. The precision of these
clinical measurements should be documented with data on
observer reproducibility.
FUNCTION
Measurements of functional impairment can be used to
identify the severity of disease in the study population.
Functional impairment should be deﬁned using a segre-
gated, validated index (see Physical Function below).
GENERAL PHYSICAL EXAMINATION
A general physical examination should be performed at
the onset of the study and again at the end of the study.
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Informed Consent should be obtained and documented in
accordance with the Declaration of Helsinki57 and studies
should be approved by an appropriate institutional review
board.
Conduct of the study
STUDY DESIGN
Studies should generally be controlled, using placebo or
an active comparator where the comparator has been
previously shown to be superior to placebo. They should
be randomized and double blind (specifying the type of
blinding procedure used), and parallel in design. Occasion-
ally, crossover studies or other study designs may be
appropriate; but it would be very unusual for unblinded or
uncontrolled studies to be considered acceptable by regula-
tory agencies for purposes of registration. Studies may
evaluate joints in both hands, or only in one hand; several
joints, a single row of joints or just a single joint; depending
on the research question being posed.
Studies may include an optional screening visit in
addition to a baseline visit. Two pretrial visits allow the
collection of more reliable baseline data (assuming absence
of a washout period), and can increase assurance that
patients fulﬁll entry criteria. They may also help to reduce
noncompliance and may facilitate the collection of biological
specimens. Consecutive patients enrolled for studies
should be randomized for assignment, to treatment groups
using validated randomization protocols.
At each visit, weight and vital signs (blood pressure,
pulse) should be recorded and a report of adverse experi-
ences obtained (see below).
In order to minimize variation in patient assessment, it is
recommended that the same examiner should examine the
same patient at each visit, preferably at the same time of
day, throughout the duration of the trial.
STUDY OUTCOMES
Primary outcomes
Efﬁcacy studies should specify a single, clearly deﬁned,
predetermined primary outcome variable or index. The
choice of this outcome measure will depend upon the
type of drug to be studied, the treatment effect of interest,
and the speciﬁc objectives of the study.
Alternatively several primary outcome variables may be
considered; but with this latter approach determination of
signiﬁcance will require appropriate adjustments for multiple
analyses (see Statistical considerations below).
Secondary outcomes
The inclusion of one or more secondary outcome mea-
sures may strengthen the study design. Collection of infor-
mation on secondary outcome variables should not interfere
with collection of data on the primary outcome measure.
EXAMINER
The methods used for training the examiner and for blind-
ing the examiner and the patients must be speciﬁed. Some
studies may require both a blinded investigator to assess
the patient for efﬁcacy and adverse events, and anunblinded investigator to administer the test medication/
treatment and monitor toxicity.
WASHOUT REQUIREMENTS
Symptom-modifying drugs/treatments
All studies of symptom-modifying treatments require dis-
continuation of previous analgesic and anti-inﬂammatory
medications, including topical agents, prior to initiating treat-
ment with the test drug/therapy, in order to permit the eval-
uation of unmodiﬁed severity of pain. The duration of the
pretrial drug withdrawal should be determined by the time
required for the clinical effect to disappear (e.g., 5 half-lives
of the drug). During this washout period, subjects may need
rescue analgesia (e.g., acetaminophen (paracetamol) up to
4 g/d). This must be discontinued sufﬁciently long before
the clinical evaluation, for the interfering effects of the
rescue drug to disappear.
Worsening of symptoms during the washout period,
although not a necessary prerequisite for subject inclusion
into the trial, should be documented. The possible merits
of including a so-called ‘‘ﬂare design’’ should be consid-
ered, although it is currently recognized that this is an issue
that requires further research. In all studies of symptom-
modifying treatments a speciﬁed level of symptoms is
required for entry to the study.
There are a variety of ‘‘nutriceuticals’’ and alternative
medicine products that are available and widely used by pa-
tients. The efﬁcacy of some of these products has been
tested in clinical trials. The use of such agents needs to
be considered in the design of all OA treatment trials. Pref-
erably their use should be excluded. Alternatively, if their
use is to be continued it is recommended that patients
should be taking a stable dose for a minimum of 3 months
prior to entry to the study.
Structure-modifying drugs/treatments
A washout period may not be required in trials of struc-
ture-modifying drugs/treatments. If, however, the effect of
the treatment on symptoms is to be tested, the use of
a washout period should be considered. Because of pos-
sible effects of nutriceuticals and alternative products on
disease progression, their use is precluded in trials of
structure-modifying agents.
ADMINISTRATION OF STUDY MEDICATION/TREATMENT
Control agents may include placebo or active agents (e.g.,
analgesic or NSAID). Use of placebo may be inﬂuenced by
ethical considerations or the requirements of regulatory
agencies. The use of active comparators allows demonstra-
tion of equal or improved efﬁcacy over existing therapies.
However, they require prior validation as a reference treat-
ment, and studies using active agents as comparators may
require larger numbers of subjects, than placebo controlled
trials, as they require the use of a noninferiority trial design.
Topical
Topical test medications should be dispensed in con-
tainers that are identical in appearance to those containing
the comparator (active drug or placebo). The comparator
should mimic the test medication in appearance, odor and
local effects on the skin. Clear verbal and written instruc-
tions regarding use must be provided for patients. These
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Compliance should be veriﬁed by weighing returned tubes,
measuring amounts of returned liquid, or any other quanti-
tative method more appropriate to the composition and pre-
sentation of the product. Placebo responses are particularly
frequent with topical drug delivery, and this should be con-
sidered in protocol design and data interpretation. As topical
therapy is predominantly a local form of treatment, joints to
be treated and evaluated must be carefully predeﬁned in all
studies of topical agents.
Oral
Standard procedures for testing oral medications in hip
and knee OA should be adopted in hand OA studies1.
In studies of structure-modifying drugs concomitant med-
ication (e.g., rescue analgesia and NSAIDs) should be dis-
pensed in bottles and counted at each visit. Analgesic drugs
with a short half-life should not be taken from the evening
prior to the day of the assessment if pain is to be evaluated
as the main outcome measure.
Parenteral medications
Parenteral medications should be formulated to appear
identical to the comparator drug. If this is not possible, the
parenteral medication should be dispensed and adminis-
tered by a person other than the blinded investigator (i.e.,
by an unblinded investigator) and the injectable agent should
be concealed fromboth the patient and the blinded evaluator.
IA medications
IA study medications should be formulated to appear
identical to the comparator drug. If this is not possible, the
medication should be injected by a physician other than
the blinded investigator (i.e., by an unblinded investigator).
The volume of the control to be injected should be equal
to the volume of the test agent. The identity of the injected
agent should be concealed from both the patient and the
blinded evaluator. Placebo responses are particularly fre-
quent following intra-articular injections58, and this should
be considered in protocol design and data interpretation.
Nonpharmacologic treatments (e.g., physical,
devices, acupuncture, support programs, etc.)
A number of nonpharmacologic treatments have been
proposed for the management of hand OA. Some have
been tested in randomized controlled trials2,4,59. Ap-
proaches to blinding and the selection of appropriate control
groups may differ from those used in trials of drugs; but out-
come measurements are the same in trials of nonpharma-
cologic and pharmacologic treatments. The choice of
controls, including sham interventions, may vary, depend-
ing upon the procedure to be tested (e.g., the control group
will not be the same for the evaluation of a splint as it will be
for a program of physical exercises). Cluster randomization
of groups of patients, or therapists, may be appropriate
when assessing certain nonpharmacologic treatments that
involve group intervention.
COMPLIANCE
It is essential in studies of structure-modifying drugs, that
strategies be employed to maximize and document patientcompliance. For example, telephone contact might be main-
tained with patients at 4e8 week intervals. The method of
communication and time spent with patients should be stan-
dardized as much as possible without jeopardizing the rela-
tionship with the patient.
SUBJECT RETENTION
Every effort should be exercised to maintain contact with
patients, even when their participation in the study has had
to be terminated earlier than planned (drop-outs). In all
cases of premature discontinuation, a clinical assessment
should be made (at least by a telephone call) and a radio-
graphic examination should be routinely performed in struc-
ture-modiﬁcation trials. For early termination of patients who
are agreeable, a ﬁnal visit at the original scheduled end-
point is advised and, in trials of structure-modiﬁcation, this
should include a radiographic examination.
PHARMACO-ECONOMIC ASPECTS
Sponsors should consider performing pharmaco-
economic analyses in all hand OA clinical trials60. In most
hand OA trials, such analyses would form part of a battery
of secondary outcomes requiring analysis. Depending on
the type of health economic analysis (costeeffectiveness;
costebeneﬁt; and costeutility), the analysis could be based
on relevant generic health-related quality of life and utility
measures, general arthritis measures or OA-speciﬁc mea-
sures. The conduct of health economic evaluations may
have important implications for trial design, including the
sample size, outcome measurements, trial duration and
data analysis.
USE OF CONCOMITANT MEDICATIONS
Symptom-modifying drugs/treatments
It is impractical to expect patients to participate in long-
term trials without some recourse to rescue medication for
pain. For long-term trials, the use of concomitant analgesic
medication should be permitted on a limited basis. An ex-
ample may be the use of acetaminophen (paracetamol)
for escape analgesia (up to 4 g/d). However, any escape
medication must be discontinued sufﬁciently long before
clinical assessment, to allow its effects to have warn off at
the time of assessment. Protocol design should routinely in-
clude a record of the consumption of analgesics, NSAIDs,
and IA injections. Although the use of such information as
an outcome measure in clinical trials of hand OA has not
been validated, and requires further research, it is currently
part of the battery of measurements used routinely in clini-
cal trials, and should be included as a secondary outcome
variable for efﬁcacy. Short-term trials (i.e., less than 6
weeks) may not require escape analgesia. However,
when necessary, acetaminophen could be allowed, and
its consumption monitored.
IA depocorticosteroids should not be permitted within 1
month of entry to the clinical trial55,56.
Structure-modifying drugs/treatments
Concomitant therapy may interfere with the evaluation of
outcome measures and should ideally be excluded. How-
ever, in long-term studies, it is neither ethical nor practical
to exclude all concomitant treatments. In all trials,
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likely to affect joint structure should be excluded, and res-
cue therapy should be permitted, standardized, carefully re-
corded and monitored. As noted above, subjects may use
acetaminophen (paracetamol) for escape analgesia (up to
4 g/d), provided they discontinue acetaminophen, in sufﬁ-
cient time, prior to the study assessments.
The consumption of analgesics, NSAIDs, IA injections,
topical agents, and nonpharmacologic interventions should
be documented at each visit. There is, however, a need to
develop methods to control the effects of these potentially
confounding variables.
CONCOMITANT NONMEDICINAL THERAPY
Concomitant treatment with physical and/or occupational
therapy should be either standardized or adjusted for the
analysis, to ensure that the effects of exercise programs
on disease progression do not bias the outcome of the study.
Information on weight change (reduction or gain), introduc-
tion of, or changes in, the use of splints; and introduction
of, or changes in, physical or occupational therapy during
the study should be recorded, and prespeciﬁed, in the
protocol.
LABORATORY TESTS
For most multicenter studies, routine laboratory tests
(complete blood counts, urinalyses and serum chemistry
determinations) should be performed in a central laboratory.
ADVERSE EVENTS
These should be carefully recorded and described and, if
severe, immediately reported to regulatory authorities, in
accordance with requirements for good clinical practice
(GCP). All adverse events occurring during a trial should
be followed up until complete resolution or stabilization
has occurred. Safety considerations in hand OA trials
should follow general recommendations for the conduct of
clinical trials in patients with OA (see Ref. 1).
PROTOCOL VIOLATION
See in Ref. 1.
CASE REPORT FORMS AND SUPPLIES
See in Ref. 1.
Outcome measures for symptom-modifying trials
Instruments used to measure outcomes in clinical trials of
OA should be valid, reliable, responsive to change and feasi-
ble. Clinical trials in hand OA should use validated instru-
ments that have been used in previously published studies,
thus permitting comparison of results across trials of different
therapeutic interventions (Table IV). Consensus on three
core set clinical measures for OA clinical trials was reached
at the Outcome Measures in Rheumatology Clinical Trials
(OMERACT) III Conference61, andwas subsequently ratiﬁed
by the OARSI Task Force on Clinical Trials Guidelines1. The
core set clinical measures speciﬁed in the original OMER-
ACT and OARSI Task Force OA Clinical Trials Guidelines
were: pain, physical function and patient global assessment;
and for studies 1 year in duration: joint imaging.Tools for the assessment of patient reported outcomes
(PRO) fall into two basic acquisition categories, those which
are doctor-administered, two of which, the Cochin In-
dex62,63 and the FIHOA44e47, are illustrated in the Appendix
to these Guidelines; and those which have been designed
for patient self-administration, such as the Arthritis Impact
Measurement Scales (AIMS, AIMS2)64,65, the Australian/
Canadian Hand Osteoarthritis Index (AUSCAN)48e54, the
European Quality of Life Measure (EuroQol)66,67, Health
Assessment Questionnaire (HAQ)68, Health Utilities Index
(HUI)69,70, Nottingham Health Proﬁle (NHP)71,72 and Short
Form 36 (SF-36)73.
The tools can also be classiﬁed according to whether
they are of generic quality of life measures such as the
EuroQol66,67, HUI 369,70, NHP71,72 and SF-3673; general
purpose arthritis measures such as the AIMS/AIMS264,65
and HAQ68; or disease-speciﬁc measures such as the AUS-
CAN48e54, the Cochin Index62,63, the FIHOA44e47 and the
Score for Assessment and quantiﬁcation of Chronic Rheu-
matic Affections of the Hands (SACRAH), a self-adminis-
tered instrument which was initially developed for use in
both in RA and hand OA patients at the same time74. The
responsiveness of this instrument remains to be studied.
The tools can also be distinguished according to whether
they are, or not, copyrighted. Among hand OA-speciﬁc
instruments, the AUSCAN is copyrighted, and the Cochin
Index, the FIHOA and the SACRAH are not.
The following characteristics and features of hand OA-
speciﬁc instruments have been reported in the peer
reviewed literature. The instruments are presented in alpha-
betical order.
AUSCAN INDEX48e54
The patient-centered self-administered Australian/Cana-
dian (AUSCAN) Index is a valid, responsive and feasible
tri-dimensional (pain, stiffness, and function) index devel-
oped speciﬁcally for hand OA studies (Table V). The teste
retest reliability (ICC¼ 0.70e0.90), internal consistency
(Cronbach’s alpha¼ 0.90e0.98), face, content and criterion
validity (vs FIHOA, HAQ, Doyle Index, PGA, MDGA, grip
strength, pinch grip and duration of morning stiffness) and
responsiveness of the AUSCAN Index have been reported
in a previous issue of this journal48,49. Comparative studies
of the AUSCAN and a self-administered application of
the FIHOA, which is not the validated form of the index,
since the FIHOA has only been validated as a doctor-
administered index, have been performed49. Since it was
ﬁrst developed, thirty-one alternate-language translations
of the AUSCAN Index have been created, linguistically
validated and are currently in use.
The original validation studies were conducted on 5-point
LK and 100 mm visual analog (VA) scaled formats of the in-
dex, although an 11-point numerical rating scale (NRS) ver-
sion is also in use. Like the Cochin Index, the AUSCAN
Index has been validated in both OA and RA patients54,63.
AUSCAN Index scores show comparable associations with
grip strength and with radiographic severity of hand OA52.
Post-validation experience with the AUSCAN Index in
efﬁcacy studies and licensing studies of new pharmaceuti-
cal products has conﬁrmed the responsiveness of the
AUSCAN Index, in phase 3 clinical trials50,51.
COCHIN INDEX62,63
The Cochin hand functional disability scale is a unidimen-
sional doctor-administered index, and a modiﬁcation of the
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Summary of clinical outcomes and techniques for use in hand OA trials
Tool or instrument Recommended Could be recommended
may require further
validation or precision
on instrument
Could be interesting
but requires validation
Case deﬁnition ACR criteria;
KellgreneLawrence
radiographic scale
Use of photographs;
Patient self-deﬁnition
for epidemiological studies
Clinical assessment
Pain assessment Global pain on a VAS
AUSCAN pain subscale
Function assessment:
Hand OA-speciﬁc AUSCAN function subscale,
Cochin Hand OA scale, FIHOA
Nonhand OA-speciﬁc
instruments (need to extract
hand OA relevant items)
AIMS1/AIMS2 HAQ
Patient’s global
assessment
Recommended but no validated
formulation of a standard question
Standard question
Quality of Life SF-36, SIP,
EuroQol, NHP
Stiffness Duration (min)AUSCAN stiffness
subscale
Joint examination:
Deformity, Pain on pressure
Bouchard/Heberden nodes Jeweler’s ring,
Doyle modiﬁcation
of the Ritchie Index
Performance-based measure Backman Test
Aesthetic damage assessment To be determined
Escape medication NSAIDs and analgesics consumption
although not validated must be
monitored and recorded
Response criteria Certainly useful.
To be determined
and validatedindex developed by Duruo¨z et al.62 for use in rheumatoid ar-
thritis hand studies. The index has been revalidated in hand
OA patients, and the validity, responsiveness and feasibility
of the Cochin Index have been reported in a previous issue
of Osteoarthritis and Cartilage63. Index scores correlate with
FIHOA scores (Spearman coefﬁcient, r¼ 0.87), and pain
severity scores. The Cochin Index contains 18 questions
concerning daily living activities, rated on a 6-point scale
(from 0¼ yes possible without difﬁculty to 5¼ impossible
to do) (Table VI). The total score ranges from 0 to 90. A fac-
tor analysis demonstrated that four factors accounted for
65% of the total variance. The ﬁrst two factors related to ac-
tivities requiring grip strength and activities requiring dexter-
ity and precision. The mean time for administration was
reported to be around 3 min in RA patients62. A comparative
analysis of various instruments was performed to identify
which of these instruments discriminated best between pa-
tients who had improved and patients who had deteriorated.
The four best instruments were, by statistical rank: the
global handicap rated on a VAS, the Cochin Functional in-
dex, the global pain on a VAS and the FIHOA. The Cochin
Index exhibited a greater Standardized Response Mean
(SRM), compared to that of the FIHOA in the 19 patients
who deteriorated (0.75 vs 0.38), but in patients who
had improved, the FIHOA showed a better SRM (0.42 vs
0.30) than the Cochin Index63. The Cochin Index is avail-
able in French and English validated formats.
FIHOA44e47
The FIHOA44e47 is a unidimensional doctor-administered
index and was the ﬁrst index validated for use in patientswith hand OA (Table VII). The FIHOA is a valid, responsive
and feasible measure of physical disability in hand OA pa-
tients44,45. The FIHOA contains 10 questions and scores re-
sponses on 4-point verbal rating scales to avoid any
‘‘centralization’’ of the answers (the total score ranges
from 0 to 30) (Table VII).
Data on its responsiveness have been published in a pre-
vious issue of this journal45 and have shown that it is a little
less responsive than global pain assessment on a VAS in
a 6-month trial performed in painful hand OA patients
(SRM¼ 0.58 vs 0.87). A minimum score of 4e5 (range
0e30) seems to discriminate appropriately between symp-
tomatic and nonsymptomatic hand OA patients44. It is
easy to perform and not time consuming (2.5 min in aver-
age for completion). Since it was ﬁrst introduced, seven lin-
guistically valid alternate-language translations of the
FIHOA have been created, and are currently in use. The
FIHOA score shows comparable associations with grip
strength and with radiographic severity of hand OA46.
Post-validation experience with the FIHOA Index in efﬁcacy
studies has conﬁrmed the responsiveness of the FIHOA
Index in clinical trials47.
Regardless of the PRO instrument selected, measure-
ments should be recorded at baseline and serially at appro-
priate intervals. For studies of drugs designed to improve
symptoms, the primary outcome variable is usually joint
pain reported by the patient. Measurement should be seri-
ally recorded at appropriate intervals, at least monthly.
The exact schedule is dependent on the target joint se-
lected, the study design and the research objective.
In a systematic search and critical review of measures of
disability for use in hand OA, which included the AIMS2,
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The Cochin hand functional disability scale*
In the kitchen
1. Can you hold a bowl?
2. Can you seize a full bottle and raise it?
3. Can you hold a plate full of food?
4. Can you pour liquid from a bottle into a glass?
5. Can you unscrew the lid from a jar opened before?
6. Can you cut meat with a knife?
7. Can you prick things well with a fork?
8. Can you peel fruit?
Dressing
9. Can you button your shirt?
10. Can you open and close a zipper?
Hygiene
11. Can you squeeze a new tube of toothpaste?
12. Can you hold a toothbrush efﬁciently?
At the ofﬁce
13. Can you write a short sentence with an ordinary pen?
14. Can you write a letter with an ordinary pen?
Other
15. Can you turn a round door knob?
16. Can you cut a piece of paper with scissors?
17. Can you pick up coins from a table top?
18. Can you turn a key in a lock?
Scoring System: 0¼ yes without difﬁculty; 1¼ yes with a little dif-
ﬁculty; 2¼ yes with some difﬁculty; 3¼ yes with much difﬁculty;
4¼ nearly impossible to do; 5¼ impossible to do. Refer to: Poir-
audeau et al.63.
Table V
Australian/Canadian (AUSCAN) hand OA index: subscale structure
and item content list (Adapted with permission from AUSCAN User
Guide II)*
Pain subscale
1. Rest
2. Gripping
3. Lifting
4. Turning
5. Squeezing
Stiffness subscale
6. First wakening
Physical function subscale
7. Turning taps/faucets
8. Turning a round doorknob or handle
9. Doing up buttons
10. Fastening jewelry
11. Opening a new jar
12. Carrying a full pot
13. Peeling vegetables/fruits
14. Picking up large heavy objects
15. Wringing out wash cloths
 The AUSCAN Index is patient self-administered and avail-
able in three scaling formats: 5-point LK, 100 mm VA, and 11-
point NRS
 AUSCAN website at www.auscan.org.
 AUSCAN User Guide available
 Alternate-language translations currently available and in
use: Australia, Austria, Belgium (French, Flemish), Canada
(English, French), Czech, Denmark, Finland, France, Ger-
many, Hungary, Iceland, Israel, Italy, Lebanon, The Nether-
lands, New Zealand, Norway, Poland, Romania, Russia,
Slovakia, South Africa (English, Afrikaans), Spain, Sweden,
Turkey, United Kingdom and USA (English, Spanish).
Refer to: Bellamy et al.46,47.AUSCAN, Cochin Index, FIHOA and HAQ, Dziedzic et al.75,
using quality assessment criteria, noted that the AIMS2 and
the AUSCAN Index were more highly rated than the FIHOA,
Cochin and HAQ.
The Task Force came to the conclusion that at the pres-
ent time no one instrument can be recommended over an-
other and that the choice of instrument(s) for a speciﬁc
project will depend on the study design and the research
questions being asked. Further comparisons of the instru-
ments within the same hand OA trials are needed.
PAIN
The measurement of pain is a core set outcome mea-
sure. Pain should be measured using a single item or
multi-item 100 mm VA, 11-point NRS or LK scale76. Pain
is usually measured on one or more rating scales which
grade perceived pain severity in one or more of the several
situations, e.g., pain at rest, pain on motion, or global pain
during a speciﬁed recall period, which is often 24 h or
48 h76. The OARSI Hand Osteoarthritis Task Force recom-
mends using a single item global pain VAS for the selection
of patients for study inclusion, and for subsequent pain as-
sessment during the course of the study, either the pain
subscale of the AUSCAN Index48e54 or a single item global
pain scale. To assess global pain, a standard question
could be asked e.g.: ‘‘How much pain in your hand did
you experience during the last 48 hours?’’
Since pain may vary dramatically over time and ‘‘jump’’
from a joint to another, pain assessment should be per-
formed over deﬁned periods of time. This can be achieved
by the use of personal daily diaries where patients are asked
to record the amount of pain in the target hand, or by using
the ‘‘weekly self-assessment of painful joints’’ that has pre-
viously been proposed but not yet fully validated77.
While useful in the measurement of generalized arthritis,
the HAQ pain subscale68, or the pain subscales of the
AIMS64 or AIMS265 are of qualiﬁed value for phase 3
hand OA clinical trials, since they do not speciﬁcally assess
pain attributable to the hand joints. It is suggested that in or-
der to use generalized OA measures for this purpose (HAQ,
AIMS, AIMS2), questions relating to pain speciﬁcally refer-
able to hand joint OA may need to be selected out from
the instrument64,65,68.
PHYSICAL FUNCTION
The measurement of physical function is a core set out-
come measure. Physical function/disability is usually
Table VII
The dreiser FIHOA e English version validated with the help of
Boulos Haraoui
1. Are you able to turn a key in a lock?
2. Are you able to cut meat with a knife?
3. Are you able to cut cloth or paper with a pair of scissors?
4. Are you able to lift a full bottle with the hand?
5. Are you able to clench your ﬁst?
6. Are you able to tie a knot?
7. For women e Are you able to sew? For men e Are you able to
use a screwdriver?
8. Are you able to fasten buttons?
9. Are you able to write for a long period of time?
10. Would you accept a handshake without reluctance?
Scoring system: 0¼ possible without difﬁculty; 1¼ possible with
slight difﬁculty; 2¼ possible with important difﬁculty; 3¼
impossible. Refer to: Dreiser et al.44,45.
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grades the perceived severity or degree of disability in one
or more activities of daily living (e.g., turning taps/faucets
on, opening a new jar)78. The majority of previous hand OA
studies have not used standardized health status measures
of physical function59. Function should be measured using
the AUSCAN Index48e54, the Cochin Index62,63 or the FIHOA
Index44e47.
PATIENT ASSESSMENT OF GLOBAL STATUS
The patient’s assessment of his/her global status should
be measured using a LK, NR or VA scale. There is currently
no validated standard question, and no standard response
format for conducting this measure4,59,78. The optimal
method by which this should be measured is not well estab-
lished. However, a standard question could be asked e.g.,
‘‘Considering all the ways your hand OA affects you, how
have you been during the last 48 hours?’’ Despite the limi-
tation of the method, patient global assessment is a core set
outcome measure. The proposed formulation could be val-
idated through further studies.
PHYSICIAN ASSESSMENT OF GLOBAL STATUS
A measure of the physician assessment of global status
may be required in some cases. There is no generally
accepted method for measurement of this variable. A stan-
dard question such as ‘‘Considering all the information you
have, how is the patient’s hand OA today?’’ could be used,
responses being recorded on a VA, NRS or LK scale.
Physician global assessment is not a core set outcome
measurement.
QUALITY OF LIFE SCALES
Measurement, at appropriate intervals, of health-related
quality of life and utility is recommended; although, these
are not currently core set outcome measures1,61,79. They
not only allow measurement of the patient’s quality of life
or the utility of their health status, but also facilitate phar-
maco-economic analyses and cross-disease comparisons
of outcome. To date, there is no experience with these
instruments in OA hand trials. Examples of health-related
quality of life instruments include the SF-3673, Sickness
Impact Proﬁle (SIP)80, NHP71,72 and EuroQol66,67. Utility
can be measured using the EuroQol or HUI66,67,69,70.
JOINT EXAMINATION
The clinical examination provides an opportunity to
detect, tenderness, range of movement, bony enlargement
and inﬂammation. Previous hand OA studies have included
measurement of tenderness by palpation, pressure (see
below) or by dolorimeter; measurement of joint swelling
using jeweler’s rings; quantitation of the number of inﬂamed
Heberden’s nodes and/or measurement of joint range of
motion4,59.
Pain
The Doyle modiﬁcation of the Ritchie Index has not been
speciﬁcally validated for hand OA clinical trials2,3, but its
basic clinimetric properties in OA have been previously pub-
lished81. Dolorimeter assessments do not appear to be
reliable59.Mobility
Range of motion has shown inconsistent intrarater reli-
ability. It is possible to improve consistency of examination
if the examiner undergoes training.
Deformity
Measurements of deformity may involve assessment of
bony enlargement or angular deviation. In OA, bony en-
largements such as Heberden’s nodes, Bouchard’s nodes
or knobbly deformity at the ﬁrst CMC need to be recorded.
Jeweler’s rings may be used to quantify joint circumference.
However, training sessions may be needed to establish re-
liable measurements82. Although not a core set outcome
measure, the presence of deformity should be recorded
on the screening visit and at endpoint in long-term clinical
trials assessing both structure and symptom-modiﬁcation.
This can be conducted as part of the physical examination
proposed in General physical examination, and performed
at baseline and termination visits.
Inflammation
For both the description of the study population and the
assessment of changes following treatment it may be useful
to record the number and location of inﬂamed joints, as de-
ﬁned by redness and soft periarticular or articular tissue
swelling. This should be done at the screening visit and,
as a minimum, at the endpoint of the study.
PERFORMANCE-BASED MEASURES
Performance-based measures, which include such tech-
niques as grip strength have been studied83, to some
extent, but how these measures vary over time is un-
known59,82,83. The Backman’s hand function test has
been developed to explore some aspects of both hand func-
tion and performance, such as grip strength and pinch grip;
and has been used in a clinical trial59,84. It has been used
by physical and occupational therapists to measure im-
provement in functional capacity, but its responsiveness
has not been studied in hand OA. Its use requires speciﬁc
devices, trained investigators, and it is time consuming.
Performance-based measures are not currently core set
outcome measures.
STIFFNESS
The duration and severity of joint stiffness can be
assessed, but these are also not core set measures.
There is currently no standard wording for questions
relating to the duration of joint stiffness in handOA.When du-
ration of stiffness is used as an outcome measurement,
a standard question such as ‘‘What is the duration of stiffness
in your ﬁnger joints in the morning?’’ (expressed in minutes)
is recommended. Based on experience in hip/knee OA, pa-
tients need to have a clear understanding of reference points
for the onset (‘‘on ﬁrst wakening’’ vs ‘‘on getting out of bed’’)
and the offset (‘‘starts to ease off’’ vs ‘‘when ﬁngers are as
limber as they will be for the rest of the day’’) of joint stiffness
in order to estimate its duration. When the severity of stiff-
ness is to be measured in clinical trials, the AUSCAN Index
stiffness subscale may be used48e54.
AESTHETIC DAMAGE ASSESSMENT
The Task Force recognized the potential importance of
a measure of aesthetic damage. The extent to which
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and especially for women with hand OA, has not been sys-
tematically assessed or quantiﬁed. The task force was un-
aware of any instrument currently available that has the
capacity to make suchmeasurements and the impact of aes-
thetic damage is not a core set outcome measure. A stan-
dardized question, which has yet to be developed, could
help to address this issue, but needs to be explored through
further studies.
‘‘FLARES’’
The ‘‘number of ﬂares’’ and the deﬁnition of ‘‘ﬂares’’ lack
precise description. There is no validated tool currently
available to perform this measurement. It is suggested
therefore that ‘‘ﬂares’’ should not be used at this time as
an outcome measure (however, see ‘‘ﬂare design’’ as an
inclusion criterion above). This issue could be explored
through further studies.
ESCAPE MEDICATION
Analgesic and NSAID consumption should be carefully
recorded at baseline and at each visit. While escape
medication usage has not been validated as an outcome
for hand OA clinical trials, it certainly provides important
information, and should be recorded in clinical trials.
RESPONSE CRITERIA
There are no deﬁnitions of minimum clinically important
responses for any of the above measures in OA of the
hand. As there is no published data which can be used to
set predetermined threshold values for improvement, as
has been recommended for hip and knee OA studies85,86,
the Task Force cannot currently recommend the use of
any speciﬁc individualized response criteria for adjudicating
responses to treatment in hand OA studies85,86. Further re-
search is needed to develop such responder criteria for
hand OA studies. This objective could be approached, by
incorporating response-based research questions in future
clinical trial protocols.
Outcome measures for structure-modifying trials
For studies of potential structure-modifying drugs, the pri-
mary outcome variable should be a measure of joint mor-
phology; such as an imaging modality. Clinical follow-up
of patients participating in trials of structure-modifying drugs
should be at 3 intervals of 3 months or less.
JOINT IMAGING
The plain radiograph remains the most available and stan-
dardized method for the evaluation of hand OA2,3,37,40,41.
The separation of nonerosive from erosive OA remains con-
troversial87. It is anticipated, that as magnetic resonance im-
aging (MRI) becomes more readily available and more
affordable, measurements currently undertaken with joint
radiographs will be performed by MRI88,89. However, further
prospective studies of MRI are needed before MRI can
replace the radiograph, for clinical trials of structure-
modiﬁcation of the hand. Patient selection for structure-
modifying trials may be informed by the radionuclide bone
scan, since localization of the nuclide to particular bony sites
may predict future progression of disease90,91. However,radionuclide bone scans are not readily available at all inves-
tigator sites and the examination is time consuming and
expensive. The Task Force does not recommend the routine
use of radionuclide bone scans to select patients at risk of
radiographic progression, for structure-modiﬁcation trials.
The computerized, digital, infrared, thermal imaging pro-
posed byKraus et al.92may, in future, help to identify patients
at risk of rapid progression of structural changes of hand OA
at a stagewhen radiographic changes are absent orminimal.
While the technique may have some value in the selection of
patients at risk of radiographic progression, the method
requires further validation in longitudinal studies92.
Radiographic technique
For symptom-modifying trials, where a radiograph is ob-
tained for diagnostic purposes, a single postero-anterior ra-
diograph of both hands with the hands parallel on the same
cassette is acceptable. Quantitative microfocal radiography
may offer advantages over routine radiography, but is not
readily available93. Digitized images do not provide addi-
tional information for interpretation94. Computed tomo-
graphic images do provide better deﬁnition of changes,
but the techniques have not been extensively tested95.
For structure-modifying trials, a postero-anterior radio-
graph of each hand on separate cassettes should be ob-
tained. It is recommended that the radiographs be
obtained at the point of enrollment in the study and again
at yearly intervals. A hand map is recommended for repro-
ducibility of position. In order to assure a standardized tech-
nique, data on the initial radiograph should include type of
radiographic ﬁlm, type of radiographic cassette, kilovolts,
milliseconds, and milliamperage. These should be identical
in subsequent studies. Unless there is a special reason, the
ﬁrst CMC joint does not need to be imaged separately96.
It is anticipated that in many future trials, ﬁlms (whether
they have been taken as plain or digitized radiographs)
will be digitalized and loaded on CDs or DVDs for reading
and analysis in a central center. Digitalized ﬁlms will be
read on a computer screen, rather than on a light box,
and this will allow magniﬁcation of the images.
Readers
The trial design should specify the number of radiographs
and any special training required for radiograph readers.
Although a single, well-qualiﬁed reader may sufﬁce97, it is
of note that one previous study compared different readers
and recommended three for internal consistency98. It has,
however, not been proven that using 2 or 3 readers is supe-
rior to using one single trained reader. A recent study per-
formed in hip OA, which compared two readers vs one,
did not observe any advantage in using more than one
trained reader; and recommended that the ‘‘best’’ reader
be selected, among several, before starting the trial99.
The use of a single reader is likely to improve longitudinal
sensitivity to change; and so help to minimize the number
of patients needed to be included. Training sessions usually
improve the consistency of the readings. The reader may
be any trained specialist. However, since no radiographic
scoring method has been extensively validated in hand
OA, and since little is known with respect to how these grad-
ing methods capture changes over time, the use of 2
readers could be considered98. When there is more than
one reader, the trial design needs to specify how differ-
ences in readings will be adjudicated and how data will be
analyzed (i.e., each reader’s scores, mean of the scores
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regarding the number of readers that is optimal must await
the results of further research. The goal is for radiographs to
be read with high levels of inter-reader and intrareader pre-
cision. Protocols should include speciﬁcation of the preci-
sion of the method employed (i.e., inter-reader, cross-
sectional and longitudinal intrareader reproducibility and
sensitivity to change should be speciﬁed).
For all trials, the radiographs should be masked for the
patient name and the radiograph should be identiﬁed by
a code. For both symptom and structure- modifying trials,
the prestudy ﬁlms should be evaluated, prior to entry into
the study, to conﬁrm the diagnosis.
For structure-modifying trials, all ﬁlms from a single
patient should be evaluated at the same time after the ﬁnal
ﬁlms have been obtained. For most studies, the radiographs
of each patient should be masked and labeled in random
order; so that the reader is blinded as to the sequence
and the date the radiograph was obtained, as well as to
the treatment given. If the protocol allows the reader to be
aware of the time sequence, this potential source of bias
should be identiﬁed in the protocol, and an appropriate
explanation and justiﬁcation provided. It can, however, be
anticipated that any potential bias that might result from
the reader’s knowledge of the time sequence of the ﬁlms
will not affect conclusions in a double-blind experiment,
where the reader has been blinded to the nature of the treat-
ment arms. For intrareader reproducibility, a prespeciﬁed
number of pairs of baseline and endpoint radiographs
should be re-read (testeretest) at each session and be-
tween sessions. Re-reading of radiographs allows calcula-
tion of the intrareader cross-sectional and longitudinal
variability99. If there is more than one reader, inter-reader
variability should also be calculated using the same sample
pairs of radiographs.
Joints examined
The protocol should specify which joints are to be radio-
graphically evaluated. In some studies this may include
up to 16 joints (one hand) or 32 joints (both hands), includ-
ing MCPs, ﬁrst CMC and scapho-trapezial joints.
All trials should include a radiograph of all the distal inter-
phalangeal (DIPs), proximal interphalangeal (PIPs) joints,
and the ﬁrst CMC (or trapeziometacarpal) joints. However,
some protocols may be designed not to evaluate all DIP and
PIP joints, while others may elect to include all DIP, PIP, ﬁrst
IP joint, and the metacarpo-phalangeal (MCP) joints.
Anatomic changes examined
All trials need to record changes in the above joints that
reﬂect joint space narrowing and presence of osteo-
phytes33,91,98,100,101. Additional measurements to be in-
cluded are erosions, subchondral sclerosis, subchondral
cysts and deformity38. The protocol should deﬁne each of
these features and how they are to be recorded. Although
osteophytes or joint space narrowingmight bemore sensitive
to change in the evaluation of progression, measurement of
all radiographic features is recommended at this time99,102.
Measurement of the above radiographic features may
be performed using a global scale27,38,41,101,103, by a sum-
mation score, or by the individual features (Tables VIII and
IX)2,27,28,41,91,104. These features may be recorded as pres-
ent/absent or graded using ordinal, interval or ratio scales.
A LK scale of 0e3 (0¼ absent; 1¼mild; 2¼moderate;3¼ severe) may be used. Atlases have been published to
improve standardization of ratings of individual radiographic
features28,37.
Different published methods offer advantages that may be
applicable for a particular trial design. A summation score
maybe adequate for disease classiﬁcation and for population
surveys. In addition, for structure-modifying trials, the Task
Force is of the opinion that none of the presently available
global scales or summation scores has been adequately
validated or compared with others. Although the individual
features have also not been adequately validated in prospec-
tive trials, the Task Force recommends that individual radio-
graphic features in each of the selected joints should be
recorded for each joint. Alternative methods using factor
analysis to determine optimal combinations and weightings
of various radiographic features, can be considered, but
these require validation in hand OA studies. If summation
scores are to beused, they should be conﬁned to speciﬁc fea-
tures (e.g., osteophytes). In particular, investigators should
avoid combining the ratings of osteophytes and joint space
narrowing, unless the proposedmethod has been previously
validated. In all studies the primary radiographic outcome
measurement to be used must be prespeciﬁed.
Table VIII
Numerical and anatomical radiographic scoring system for the as-
sessment of hand OA by Verbruggen. Points attributed to changes
in osteoarthritic joints
Osteophytes Appearance/
disappearance
þ1.0/1.0
Increase/decrease in size þ0.5/0.5
Joint space Narrowing/widening þ1.0/1.0
Subchondral cysts Appearance/
disappearance
þ1.0/1.0
Increase/decrease in size þ0.5/0.5
Refer to: Verbruggen et al.27,41,101.
Table IX
Radiographic scoring scale for hand OA proposed by Kallman. Rat-
ing methods used in scales for grading individual features of OA of
the hand
Feature Grade
Osteophytes 0¼ none
1¼ small (deﬁnite) osteophyte(s)
2¼moderate osteophyte(s)
3¼ large osteophyte(s)
Joint space narrowing* 0¼ none
1¼ deﬁnitely narrowed
2¼ severely narrowed
3¼ joint fusion at least 1 point
Subchondral sclerosis 0¼ absent
1¼ present
Subchondral cysts 0¼ absent
1¼ present
Lateral deformityy 0¼ absent
1¼ present
Collapse of central
joint cortical bone
0¼ absent
1¼ present
Refer to: Kallman et al.38,99.
*Scores are based on the amount of narrowing between bone
and plates, not on osteophyte bridging.
yDeﬁned as malalignment of at least 15 degrees.
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MRI is uniquely capable of visualizing all components of
the joint simultaneously, and therefore offers an opportunity
to assess the joint as an organ. MRI is capable of quantifying
a number of morphological and compositional parameters of
articular tissues relevant to OA. Recently developed tech-
niques for knee OA, for noninvasively quantifying cartilage
volume, thickness and water content, particularly in early
disease, show promise as potential outcome measures for
future therapeutic studies. There have been no cross-sec-
tional or longitudinal studies of MRI in hand OA. The use of
MRI for hand OA studies requires further research.
OTHER IMAGING MODALITIES
Computed Tomography, ultrasonography and scintigra-
phy have not been adequately validated and cannot currently
be recommended for use in long-term hand OA studies.
Radionuclide bone scanning may assist in identifying pa-
tients at increased risk of disease progression. Although
there is some evidence that ﬁnger joints showing increased
localization of the radionuclide are more prone toward pro-
gression91, the method cannot currently be routinely
recommended.
MOLECULAR AND GENETIC MARKERS
Disease ‘‘markers’’ have been sought to provide informa-
tion that would be useful for diagnosis, for the assessment
of the patho-physiological ‘‘activity’’ of the disease and for
assessment of prognosis. Such biological markers can in-
clude clinical features, imaging modalities, genes,that pre-
dispose to the initiation or progression of disease and
pathological features (e. g., histological, immunological, bio-
chemical or microbiological).
A variety of different biochemical markers of cartilage,
bone and synovial tissue metabolism have been investi-
gated in synovial ﬂuid, blood or urine of patients with
OA105e107. The majority of such research, however, has fo-
cused on knee or hip rather than hand OA108. Certain
markers measured in knee synovial ﬂuid, such as chondroi-
tin sulphate epitopes, differ according to presence or ab-
sence of hand OA, suggesting constitutional differences,
irrespective of which joint is sampled109. A marker (Col2-
3/4Cshort, a marker of cartilage catabolism) has been
shown to be increased in a population of hand OA patients
compared to controls, without any difference between nodal
and erosive subsets107. Nevertheless any marker for hand
OA, that is to prove clinically useful, would need to be esti-
mated in blood or urine, rather than synovial ﬂuid. Although
abnormalities in serum measures (e.g., immunoglobulin
levels, rheumatoid factor seropositivity) have been reported
in subjects with hand OA, these changes are nonspe-
ciﬁc110. Future research work is therefore required to iden-
tify biochemical markers that are more informative than
existing clinical and imaging markers with respect to early
diagnosis, disease activity and prognosis.
The importance of genetic inﬂuence on the development
of Heberden’s nodes and hand OA is well recognized, the
variance attributable to heritability being estimated at
>60%111. Such strong heritability clearly emphasizes
a need for genetic linkage and association studies, and
many such studies are currently underway. Recent studies
have revealed linkages between loci on chromosome 2q
with both multiple Heberden’s nodes112 and radiographic
hand OA113, although the genes involved have yet to beidentiﬁed. Speciﬁc genetic associations with hand OA
have, however, been reported, for polymorphisms of the
IGF-1 gene114 and aggrecan genes115 in Dutch and Amer-
ican populations respectively, and with the vitamin D recep-
tor116 and estrogen receptor117 genes in Japanese
subjects. Although such work is at an early stage, it is
hoped, that in the near future it will result in the identiﬁcation
of highly informative genetic markers for the development
and outcome of hand OA.
Statistical considerations
General statistical guidelines and recommendations for
OA studies were formulated by an earlier OARSI Task force
and published in a special report in Osteoarthritis and
Cartilage in 19961. These recommendations remain valid
and are applicable to studies of hand OA. The Task Force
on hand OA has, however, developed recommendations
for how researchers could analyze information from radio-
graphs, while recognizing that no single feature is consis-
tently associated with disease progression. The following
are guidelines for the statistical evaluation of outcomes,
with emphasis on how to evaluate more than one primary
outcome variable.
CHOICE OF OUTCOME VARIABLES
Elsewhere in this document the Task Force has recom-
mended that trials should include evaluation of DIP, PIP
and ﬁrst CMC joints and that individual radiographic fea-
tures of joints should be assessed for change.These in-
clude changes in joint space, the presence and severity of
erosions, the presence of osteophytes and possibly some
other radiographic features such as spurs, sclerosis and
deformities
However, individual radiographic features are scored and
quantiﬁed, the prespeciﬁed primary radiographic outcome,
which is subjected to statistical analysis, should be directly
related to the research objectives of the study, and should
take into consideration the polyarticular presentation of
hand OA. If the researcher or sponsor of the research hopes
to claim that a treatment is structure-modifying as assessed
by changes in joint width, spurs and erosions, then a com-
bined primary outcome variable might be appropriate. How-
ever, the pharmacological mechanism of action of the
potentially structure-modifying agent also needs to be con-
sidered. If the primary effect is expected to be conﬁned to
retardation of joint space narrowing or erosive disease,
then assessment of a single feature such as joint spacewidth
would be a more appropriate primary outcome measure.
The intended claims may, however, require evaluation of
more than a single prespeciﬁed primary outcome measure.
If, for example, the sponsor or researcher wishes to demon-
strate symptom-modiﬁcation as well as structure-modiﬁcation
of the agent to be studied it may be appropriate to have two
prespeciﬁed ‘‘co-primary’’ outcomes (one for structure-
modiﬁcation, and one for symptom-modiﬁcation) and the
power calculation for the number of subjects required will
need to take both the primary endpoints into consideration.
If the objective is to investigate whether the treatment is
also symptom-modifying, then patients included for study
will need to be experiencing at least a moderate amount of
the symptom in question at the point of enrollment.
The Task Force recommends that the radiographic fea-
tures chosen to measure change be individually scored in
a standardized, manner in all study patients, and all joints
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baseline and at all study follow-up visits. The aim is to cap-
ture change over the duration of the trial, recognizing the di-
verse presentation of hand OA, and that different joints and
joint features may be variably affected at baseline, and as
the trial progresses. One patient may present with involve-
ment of several DIPs, but only with pain in the ﬁrst CMC joint.
Another patient may present with six affected DIP and PIP
joints, only 2 of which are painful; and at the end of the study,
3 of the same joints may remain affected, with 4 others af-
fected with pain. Since standardized measurements are ob-
tained from all subjects’ radiographs, both the primary and
secondary radiographic outcome measurement scores can
be calculated for each patient. How multiple features scored
at multiple and diverse joints are to be weighted, combined
and quantiﬁed for analysis as a primary outcome, should
be made explicit in the protocol. If radiographic scales are
used, the number of joints assessed, and the way features
are summated, should be prespeciﬁed in the protocol.
As previously mentioned, there may be more than one
primary outcome reﬂecting the efﬁcacy claims for the drug
under investigation. If the chosen primary outcome has
not been previously validated, then a preliminary study
will be required to establish the validity, responsiveness
and feasibility of the outcome measure.
The Task Force recommends that the following steps be
used to analyze co-primary outcomes:
First, for each of the co-primary outcomes, values of the
test statistic more extreme than the 2-sided critical value
(for example, more extreme than 1.96 for normally distrib-
uted outcomes) provides nominal, single outcome evidence
to reject a null hypothesis, at the 2-sided 0.05 signiﬁcance
level. Some analytic methods used to compare single out-
comes among treatments have previously been outlined.
Secondly, since there are co-primary outcomes, an
adjustment in the observed P-values may be necessary to
establish the statistical signiﬁcance of outcomes. We rec-
ommend using Hochberg’s correction for multiple compari-
sons118. This method is easily implemented. For example,
suppose there are three co-primary outcomes (radiographic
change, change in pain, patient global assessment of
change). Then, (1) if all three P-values are 0.05, then all
three hypotheses are signiﬁcant, (2) if one P-value exceeds
0.05, then either (or both) of the remaining
P-values must be 0.025 to achieve signiﬁcance, (3) if
two P-values exceed 0.05, then the remaining p-value
must be .0167 for this outcome to achieve statistical
signiﬁcance. If none of the above 3 scenarios hold, then
none of the three co-primary hypotheses is statistically
signiﬁcant.
For multicenter trials of symptom-modifying treatments,
block randomization may be preferable to simple randomi-
zation to ensure that numbers of patients receiving active
treatment and control therapy are comparable as patient re-
cruitment is likely to continue over a long time. Restricted
randomization with stratiﬁcation to ensure a good balance
of key baseline characteristics of patients in the active treat-
ment and control groups may also be required in some
instances. Secondary analyses on subsets of patients
deliberately stratiﬁed for randomization between treatment
groups (e.g patients presenting with OA in the ﬁrst CMC
as the only symptomatic joint) may be of particular interest,
but intention to undertake such subset analyses should
always be clearly prespeciﬁed in the protocol.
The Task Force recommends that power calculations
for estimation of sample size, for each protocol must be
based on predeﬁned improvements in a carefully deﬁnedprimary efﬁcacy variable that is clinically relevant as well
as statistically signiﬁcant Meaningful deﬁnitions of minimum
clinically important differences in two groups of patients
exposed to different interventions, will depend on a number
of factors relating to patient characteristics, features of
disease, the nature of the intervention and the primary out-
come measures selected. Unfortunately it is not currently
possible to make ﬁrm recommendations with regard to
minimum clinically important differences when calculating
estimates of sample sizes required for hand OA studies.
Protocol developers should examine the published litera-
ture for estimates of variance that may be relevant for
sample size estimation.
Conclusion
The purpose of these Task Force recommendations,is to
provide evidence-based guidance on the design, execution
and analysis of clinical trials in hand OA, where published
evidence is available, supplemented by expert opinion
where evidence is lacking. The Task Force also hopes
that these guidelines will promote interest in, and encour-
age further investigation of, instruments and methodology
for the assessment of clinical outcomes in hand OA thera-
peutic trials. The Task Force appreciates that there are in-
sufﬁcient data currently available to provide reliable
guidance for all aspects of clinical trial design. In order
that the body of knowledge will be expanded the Task Force
supports the CONSORT statement encouraging full report-
ing of all randomized controlled clinical trials performed in
patients with hand OA to ensure not only that the details
of the design and conduct of the trials are available for
external scrutiny, but also to allow free access to the full
database.
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ACR: American College of Rheumatology.
AIMS: Arthritis Impact Measurement Scales.
AUSCAN: Australian/Canadian Hand Osteoarthritis Index.
CMC: Carpo-metacarpal.
CONSORT: Consolidated Standards for Reporting Trials.
DIP: Distal Interphalangeal.
EuroQol: European Quality of Life Measure.
FIHOA: Functional Index for Hand Osteoarthritis.
HAQ: Health Assessment Questionnaire.
HUI: Health Utilities Index.
IGCP: International Good Clinical Practice.
IP: Interphalangeal.
LK: Likert.
MDGA: Physician Global Assessment.
MRI: Magnetic Resonance Imaging.
NHP: Nottingham Health Proﬁle.
NRS: Numerical Rating Scale.
NSAIDs: Nonsteroidal Anti-Inﬂammatory Drugs.
OA: Osteoarthritis.
OARSI: Osteoarthritis Research Society International.
OMERACT: Outcome Measures in Rheumatology Clinical
Trials.
PGA: Patient Global Assessment.
PIP: Proximal Interphalangeal.
PRO: Patient Reported Outcomes.
SACRAH: Scores for Assessment and quantiﬁcation of Chronic
Rheumatic Affections of the Hands.
SF-36: Short Form 36.
SIP: Sickness Impact Proﬁle.
SRM: Standardized Response Mean.
SYSADOA: Symptomatic Slow-Acting Drug in Osteoarthritis.
VAS: Visual Analog Scale.
